RecruitingPhase 1/2

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

United States100 participantsStarted 2021-05-27

Plain-language summary

This research study is being done to help determine the safety and efficacy of gadolinium based nanoparticle, Activation and Guidance of Irradiation X (AGuIX), used in conjunction with MR-guided stereotactic body radiation therapy (SBRT) in the treatment of pancreatic cancer and lung tumors.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Presence of MRI-incompatible metal material or devices in the human body
✕. MRI-incompatible Pacemaker or defibrillator
✕. Insulin pump
✕. Aneurysm clip
✕. Artificial heart valve
✕. Cochlear implant
✕. Shrapnel or gunshot injury
✕. Cataract surgery with implant unsafe for MRI

What they're measuring

Maximum tolerated dose (MTD) Phase 1

Timeframe: 3 months

Compare Local Control at 12 months of Maximum tolerated dose MTD - Phase 2

Timeframe: 12 months

Trial details

NCT IDNCT04789486

SponsorDana-Farber Cancer Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-04-10

Contact for this trial

Jonathan Leeman, MD

(617) 732-6452 jonathe_leeman@dfci.harvard.edu

View on ClinicalTrials.gov More Non-small Cell Lung Cancer trials